|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma J, Ward EM, Smith R and Jemal A: Annual
number of lung cancer deaths potentially avertable by screening in
the United States. Cancer. 119:1381–1385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laack E, Bokemeyer C and Hossfeld DK:
Adjuvant chemotherapy after complete resection of non-small cell
lung cancer. Dtsch Arztebl Int. 105:249–254. 2008.PubMed/NCBI
|
|
4
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moriyama T, Ohuchida K, Mizumoto K, Yu J,
Sato N, Nabae T, Takahata S, Toma H, Nagai E and Tanaka M:
MicroRNA-21 modulates biological functions of pancreatic cancer
cells including their proliferation, invasion, and chemoresistance.
Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allen KE and Weiss GJ: Resistance may not
be futile: MicroRNA biomarkers for chemoresistance and potential
therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin Z, Guan L, Song Y, Xiang GM, Chen SX
and Gao B: MicroRNA-138 regulates chemoresistance in human
non-small cell lung cancer via epithelial mesenchymal transition.
Eur Rev Med Pharmacol Sci. 20:1080–1086. 2016.PubMed/NCBI
|
|
12
|
Wu S, Yuan W, Shen Y, Lu X, Li Y, Tian T,
Jiang L, Zhuang X, Wu J and Chu M: The miR-608 rs4919510
polymorphism may modify cancer susceptibility based on type. Tumour
Biol. 39:10104283177038192017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu H, Zhou Y, Liu Q, Xiao G, Wang B, Li
W, Ye D and Yu S: Association of miR-608 rs4919510 polymorphism and
cancer risk: A meta-analysis based on 13,664 subjects. Oncotarget.
8:37023–37031. 2017.PubMed/NCBI
|
|
14
|
Othman N, In LL, Harikrishna JA and Hasima
N: Bcl-xL silencing induces alterations in hsa-miR-608 expression
and subsequent cell death in A549 and SK-LU1 human lung
adenocarcinoma cells. PLoS One. 8:e817352013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mesrouze Y, Bokhovchuk F, Meyerhofer M,
Fontana P, Zimmermann C, Martin T, Delaunay C, Erdmann D, Schmelzle
T and Chène P: Dissection of the interaction between the
intrinsically disordered YAP protein and the transcription factor
TEAD. Elife. 6:e250682017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Liu CY, Zha ZY, Zhao B, Yao J,
Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors
mediate the function of TAZ in cell growth and
epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Landin-Malt A, Benhaddou A, Zider A and
Flagiello D: An evolutionary, structural and functional overview of
the mammalian TEAD1 and TEAD2 transcription factors. Gene.
591:292–303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sawada A, Kiyonari H, Ukita K, Nishioka N,
Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in
notochord development and the regulation of cell proliferation and
survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tian W, Yu J, Tomchick DR, Pan D and Luo
X: Structural and functional analysis of the YAP-binding domain of
human TEAD2. Proc Natl Acad Sci USA. 107:7293–7298. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin KC, Park HW and Guan KL: Regulation of
the hippo pathway transcription factor TEAD. Trends Biochem Sci.
42:862–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diepenbruck M, Waldmeier L, Ivanek R,
Berninger P, Arnold P, van Nimwegen E and Christofori G: Tead2
expression levels control the subcellular distribution of Yap and
Taz, zyxin expression and epithelial-mesenchymal transition. J Cell
Sci. 127:1523–1536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar :
|
|
25
|
Bragado P, Armesilla A, Silva A and Porras
A: Apoptosis by cisplatin requires p53 mediated p38alpha MAPK
activation through ROS generation. Apoptosis. 12:1733–1742. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Othman N and Nagoor NH: The role of
microRNAs in the regulation of apoptosis in lung cancer and its
application in cancer treatment. Biomed Res Int. 2014:3180302014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Touil Y, Igoudjil W, Corvaisier M, Dessein
AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G,
et al: Colon cancer cells escape 5FU chemotherapy-induced cell
death by entering stemness and quiescence associated with the
c-Yes/YAP axis. Clin Cancer Res. 20:837–846. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Benedetto A, Mottolese M, Sperati F,
Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I,
Shaaban AM, et al: The Hippo transducers TAZ/YAP and their target
CTGF in male breast cancer. Oncotarget. 7:43188–43198. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsu PC, Tian B, Yang YL, Wang YC, Liu S,
Urisman A, Yang CT, Xu Z, Jablons DM and You L: Cucurbitacin E
inhibits the Yes-associated protein signaling pathway and
suppresses brain metastasis of human non-small cell lung cancer in
a murine model. Oncol Rep. 2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Happé H, van der Wal AM, Leonhard WN,
Kunnen SJ, Breuning MH, de Heer E and Peters DJ: Altered Hippo
signalling in polycystic kidney disease. J Pathol. 224:133–142.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kelland LR, Murrer BA, Abel G,
Giandomenico CM, Mistry P and Harrap KR: Ammine/amine platinum(IV)
dicarboxylates: A novel class of platinum complex exhibiting
selective cytotoxicity to intrinsically cisplatin-resistant human
ovarian carcinoma cell lines. Cancer Res. 52:822–828.
1992.PubMed/NCBI
|
|
32
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: MiR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bian HB, Pan X, Yang JS, Wang ZX and De W:
Upregulation of microRNA-451 increases cisplatin sensitivity of
non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res.
30:202011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H, Hu B, Wang Z, Zhang F, Wei H and
Li L: miR-181c contributes to cisplatin resistance in non-small
cell lung cancer cells by targeting Wnt inhibition factor 1. Cancer
Chemother Pharmacol. 80:973–984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ye Z, Yin S, Su Z, Bai M, Zhang H, Hei Z
and Cai S: Downregulation of miR-101 contributes to
epithelial-mesenchymal transition in cisplatin resistance of NSCLC
cells by targeting ROCK2. Oncotarget. 7:37524–37535. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu HX, Wang XM, Han XD and Cao BF: MiR-608
exerts tumor suppressive function in lung adenocarcinoma by
directly targeting MIF. Eur Rev Med Pharmacol Sci. 22:4908–4916.
2018.PubMed/NCBI
|
|
38
|
Guo J, Wu Y, Yang L, Du J, Gong K, Chen W,
Dai J, Li X and Xi S: Repression of YAP by NCTD disrupts NSCLC
progression. Oncotarget. 8:2307–2319. 2017.PubMed/NCBI
|
|
39
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long
HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation
of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct.
33:326–333. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang M, Zeng J, Zhao Z and Liu Z: Loss of
MiR-424-3p, not miR-424-5p, confers chemoresistance through
targeting YAP1 in non-small cell lung cancer. Mol Carcinog.
56:821–832. 2017. View Article : Google Scholar : PubMed/NCBI
|
